Tarsus Pharmaceuticals, Inc. TARS Business Segments — Depreciation and amortization expense
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Tarsus Pharmaceuticals, Inc. in its filing.
Tagged under the XBRL concept us-gaap:DepreciationDepletionAndAmortization.
The official record: Tarsus Pharmaceuticals, Inc.’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →
Ask your AI about Tarsus Pharmaceuticals, Inc.'s business segments — depreciation and amortization expense.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Tarsus Pharmaceuticals, Inc.'s business segments — depreciation and amortization expense?
- Tarsus Pharmaceuticals, Inc. (TARS) reported business segments — depreciation and amortization expense of -$437K in Q1 2026.
- How has Tarsus Pharmaceuticals, Inc.'s business segments — depreciation and amortization expense changed year-over-year?
- Tarsus Pharmaceuticals, Inc.'s business segments — depreciation and amortization expense increased by 5.0% year-over-year, from -$460K to -$437K.
- What is the long-term trend for Tarsus Pharmaceuticals, Inc.'s business segments — depreciation and amortization expense?
- Over 3 years (2022 to 2025), Tarsus Pharmaceuticals, Inc.'s business segments — depreciation and amortization expense has grown at a 40.1% compound annual growth rate (CAGR), from $326K to $896K.
- What does business segments — depreciation and amortization expense mean?
- This metric captures the non-cash allocation of the cost of tangible and intangible assets over their useful lives within the specific business segment. It reflects the wear and tear of physical equipment or the expiration of intellectual property and other capitalized costs. Analyzing this expense is essential for calculating the segment's true cash-generating capability and capital intensity.